High-Linear Energy Transfer Irradiation Targeted to Sk
223Ra: Adjuvant or Alternative to Conventional Modalit

Clinical Cancer Research

12, 6250s-6257s

DOI: 10.1158/1078-0432.ccr-06-0841

Citation Report

#	Article	IF	Citations
1	Evaluation of the Binding of Radiolabeled Rituximab to CD20-Positive Lymphoma Cells: AnIn VitroFeasibility Study Concerning Low-Dose-Rate Radioimmunotherapy with theÎ±-Emitter²²⁷Th. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22, 469-479.	0.7	17
2	Targeted cancer therapy with a novel low-dose rate Î±-emitting radioimmunoconjugate. Blood, 2007, 110, 2049-2056.	0.6	80
3	Radionuclide Treatment in Metastasized Prostate Cancer. EAU-EBU Update Series, 2007, 5, 113-125.	0.7	4
4	Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncology, The, 2007, 8, 587-594.	5.1	461
5	Preparation of TH²²⁷-Labeled Radioimmunoconjugates, Assessment of Serum Stability and Antigen Binding Ability. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22, 431-437.	0.7	45
6	Samarium lexidronam (¹⁵³Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma. Expert Review of Anticancer Therapy, 2007, 7, 1517-1527.	1.1	62
7	Cross-sections of the reaction 232Th(p,3n)230Pa for production of 230U for targeted alpha therapy. Applied Radiation and Isotopes, 2008, 66, 1275-1280.	0.7	54
8	Alpha-particles for targeted therapy. Advanced Drug Delivery Reviews, 2008, 60, 1402-1406.	6.6	107
9	Production of ²³⁰U/²²⁶Th for Targeted Alpha Therapy via Proton Irradiation of ²³¹Pa. Analytical Chemistry, 2008, 80, 8763-8770.	3.2	41
10	PL8.4. Radioisotope treatment of bone metastases. Cancer Treatment Reviews, 2008, 34, 48.	3.4	0
11	Risks to Normal Tissues From Radionuclide Therapy. Seminars in Nuclear Medicine, 2008, 38, 347-357.	2.5	22
12	Update:Molecular Radiotherapy: Survey and Current Status. Cancer Biotherapy and Radiopharmaceuticals, 2008, 23, 531-540.	0.7	7
13	Novel Anti-Cancer Strategy in Bone Tumors by Targeting Molecular and Cellular Modulators of Bone Resorption. Recent Patents on Anti-Cancer Drug Discovery, 2008, 3, 178-186.	0.8	7
14	The Scandinavian Sarcoma Group. Monthly Notices of the Royal Astronomical Society: Letters, 2009, 80, 1-104.	1.2	16
15	Agents Targeting Prostate Cancer Bone Metastasis. Anti-Cancer Agents in Medicinal Chemistry, 2009, 9, 1079-1088.	0.9	5
16	Targeted Radiotherapy of Bone Malignancies. Current Drug Discovery Technologies, 2010, 7, 233-246.	0.6	21
17	MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of Î±-Particle Emitters for Targeted Radionuclide Therapy. Journal of Nuclear Medicine, 2010, 51, 311-328.	2.8	385
18	Stromal targeted therapy in bone metastatic prostate cancer: promise delivered. Asian Journal of Andrology, 2011, 13, 783-784.	0.8	9

#	Article	IF	Citations
19	Production of 225Ac and 223Ra by irradiation of Th with accelerated protons. Radiochemistry, 2011, 53, 73-80.	0.2	60
20	Local control of experimental malignant pancreatic tumors by treatment with a combination of chemotherapy and intratumoral 224Radium-loaded wires releasing alpha-emitting atoms. Translational Research, 2012, 159, 32-41.	2.2	22
21	Alpha Particle Radiobiology for Radium-223 (â€œAlpharadinâ€): The Fortuitous â€œGoldilocksâ€•Effect Observed for Hormone-resistant Metastatic Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 84, S708.	0.4	0
22	ComparativeIn VitroMicrodosimetric Study of Murine- and Human-Derived Cancer Cells Exposed to Alpha Particles. Radiation Research, 2012, 177, 280-287.	0.7	12
23	Production of actinium, thorium and radium isotopes from natural thorium irradiated with protons up to 141ÂMeV. Radiochimica Acta, 2012, 100, 223-229.	0.5	55
24	Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases. Cancer Letters, 2012, 323, 135-146.	3.2	88
25	A randomized, doseâ€“response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. European Journal of Cancer, 2012, 48, 678-686.	1.3	228
26	The present and future of medical radionuclide production. Radiochimica Acta, 2012, 100, 635-651.	0.5	91
27	225Ac and 223Ra production via 800MeV proton irradiation of natural thorium targets. Applied Radiation and Isotopes, 2012, 70, 2590-2595.	0.7	61
28	Advanced Clinical States in Prostate Cancer. Urologic Clinics of North America, 2012, 39, 561-571.	0.8	21
29	153Samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients. Annals of Oncology, 2012, 23, 1899-1905.	0.6	25
30	A bone marrow toxicity model for²²³Ra alpha-emitter radiopharmaceutical therapy. Physics in Medicine and Biology, 2012, 57, 3207-3222.	1.6	105
31	Therapeutic Strategies for Bone Metastases and Their Clinical Sequelae in Prostate Cancer. Current Treatment Options in Oncology, 2012, 13, 174-188.	1.3	27
32	Radium-223 for the treatment of prostate cancer. Expert Opinion on Investigational Drugs, 2013, 22, 379-387.	1.9	15
33	Dosimetry of 223Ra-chloride: dose to normal organs and tissues. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 207-212.	3.3	101
34	Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer. New England Journal of Medicine, 2013, 369, 213-223.	13.9	2,723
36	Treatment of Osteoblastic Skeletal Metastases by the Alpha-Emitting Bone-Seeker Radium-223. Medical Radiology, 2013, , 447-457.	0.0	1
37	A Randomized, Double-Blind, Dose-Finding, Multicenter, Phase 2 Study of Radium Chloride (Ra 223) in Patients with Bone Metastases and Castration-Resistant Prostate Cancer. European Urology, 2013, 63, 189-197.	0.9	154

#	Article	IF	Citations
38	Targeted radio-nuclide therapy of skeletal metastases. Cancer Treatment Reviews, 2013, 39, 18-26.	3.4	50
39	Two-Year Survival Follow-Up of the Randomized, Double-Blind, Placebo-Controlled Phase II Study of Radium-223 Chloride in Patients With Castration-Resistant Prostate Cancer and Bone Metastases. Clinical Genitourinary Cancer, 2013, 11, 20-26.	0.9	98
40	Radionuclide Therapy of Bone Metastases. , 2013, , 85-100.		0
42	Monte Carlo simulation of age-dependent radiation dose from alpha- and beta-emitting radionuclides to critical trabecular bone and bone marrow targets. Physics in Medicine and Biology, 2013, 58, 3301-3319.	1.6	10
43	Ado-Trastuzumab Emtansine and Radium 223 Dichloride. Hospital Pharmacy, 2013, 48, 729-733.	0.4	0
44	Survival Benefit With Radium-223 Dichloride in a Mouse Model of Breast Cancer Bone Metastasis. Journal of the National Cancer Institute, 2013, 105, 908-916.	3.0	83
45	Targeted Î±-Particle Therapy of Bone Metastases in Prostate Cancer. Clinical Nuclear Medicine, 2013, 38, 966-971.	0.7	46
46	Radium-223: a new treatment option for bone-metastatic CRPC. Nature Reviews Urology, 2013, 10, 630-631.	1.9	1
47	Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Management and Research, 2013, 5, 1.	0.9	101
48	Alpha-Emitter Radium-223 in the Management of Solid Tumors: Current Status and Future Directions. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e132-e139.	1.8	12
49	Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer – role of radium-223. Therapeutics and Clinical Risk Management, 2014, 10, 373.	0.9	8
50	Advanced prostate cancer – patient survival and potential impact of enzalutamide and other emerging therapies. Therapeutics and Clinical Risk Management, 2014, 10, 651.	0.9	6
51	The Potential and Hurdles of Targeted Alpha Therapy â€“ Clinical Trials and Beyond. Frontiers in Oncology, 2014, 3, 324.	1.3	142
52	Bone-Seeking Radiopharmaceuticals as Targeted Agents of Osteosarcoma: Samarium-153-EDTMP and Radium-223. Advances in Experimental Medicine and Biology, 2014, 804, 291-304.	0.8	44
53	Molecular Targeted Î±-Particle Therapy for Oncologic Applications. American Journal of Roentgenology, 2014, 203, 253-260.	1.0	62
54	Radioisotope generators of short-lived Î±-emitting radionuclides promising for use in nuclear medicine. Radiochemistry, 2014, 56, 451-467.	0.2	10
55	Radiation Safety Considerations for the Use of 223RaCl2 DE in Men with Castration-resistant Prostate Cancer. Health Physics, 2014, 106, 494-504.	0.3	59
56	Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone. Experimental Hematology and Oncology, 2014, 3, 23.	2.0	27

#	Article	IF	Citations
57	Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncology, The, 2014, 15, 738-746.	5.1	433
58	Improving the doseâ€“myelotoxicity correlation in radiometabolic therapy of bone metastases with 153Sm-EDTMP. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 238-252.	3.3	30
59	Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases. Critical Reviews in Oncology/Hematology, 2014, 91, 197-209.	2.0	15
60	Managing bone metastases and reducing skeletal related events in prostate cancer. Nature Reviews Clinical Oncology, 2014, 11, 335-345.	12.5	110
61	Radiometabolic Treatment of Bone-Metastasizing Cancer: From ¹⁸⁶Rhenium to ²²³Radium. Cancer Biotherapy and Radiopharmaceuticals, 2014, 29, 1-11.	0.7	51
62	Immunotherapy and Radiation. Seminars in Oncology, 2014, 41, 702-713.	0.8	8
63	Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncology, The, 2014, 15, 1397-1406.	5.1	351
65	A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease. Breast Cancer Research and Treatment, 2014, 145, 411-418.	1.1	95
66	Radium-223 Dichloride: A Review of Its Use in Patients with Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases. Drugs, 2014, 74, 579-586.	4.9	34
67	Challenges of managing elderly men with prostate cancer. Nature Reviews Clinical Oncology, 2014, 11, 354-364.	12.5	20
69	Radium-223 dichloride: illustrating the benefits of a multidisciplinary approach for patients with metastatic castration-resistant prostate cancer. Journal of Multidisciplinary Healthcare, 2015, 8, 279.	1.1	15
70	Well-Designed Bone-Seeking Radiolabeled Compounds for Diagnosis and Therapy of Bone Metastases. BioMed Research International, 2015, 2015, 1-12.	0.9	23
71	Targeting bone metastases in prostate cancer: improving clinical outcome. Nature Reviews Urology, 2015, 12, 340-356.	1.9	87
72	Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety. Expert Opinion on Drug Safety, 2015, 14, 1127-1136.	1.0	16
73	Bone metastases â€“ current status of bone-targeted treatments. , 2015, , 677-683.		0
74	Radium-223 dichloride: a new paradigm in the treatment of prostate cancer. Expert Review of Anticancer Therapy, 2015, 15, 339-348.	1.1	8
75	The elements of life and medicines. Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences, 2015, 373, 20140182.	1.6	164
76	Radium-223 Dichloride for Metastatic Castration-resistant Prostate Cancer: The Urologist's Perspective. Urology, 2015, 85, 717-724.	0.5	40

#	Article	IF	Citations
77	A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of ²²³Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases. Journal of Nuclear Medicine, 2015, 56, 1304-1309.	2.8	97
78	Nursing Management of Patients With Castration-Resistant Prostate Cancer Undergoing Radium-223 Dichloride Treatment. Clinical Journal of Oncology Nursing, 2015, 19, E31-E35.	0.3	1
79	Integrating Bone Targeting Radiopharmaceuticals Into the Management of Patients With Castrate-Resistant Prostate Cancer With Symptomatic Bone Metastases. Current Treatment Options in Oncology, 2015, 16, 325.	1.3	8
80	Treatment of skeletal metastases with 223Ra-chloride. Clinical and Translational Imaging, 2015, 3, 159-165.	1.1	1
81	Systemic treatment of bone metastases in castration-resistant prostate cancer (CRPC): pre-clinical to clinical point of view. , 2015, , 637-646.		1
82	New developments in the experimental data for charged particle production of medical radioisotopes. Journal of Radioanalytical and Nuclear Chemistry, 2015, 305, 247-253.	0.7	3
83	Ablation of experimental colon cancer by intratumoral²²⁴Radium-loaded wires is mediated by alpha particles released from atoms which spread in the tumor and can be augmented by chemotherapy. International Journal of Radiation Biology, 2015, 91, 179-186.	1.0	17
85	New cancer therapies and jaw necrosis. British Dental Journal, 2015, 219, 203-207.	0.3	31
86	Alpha Emitter Radium 223 in High-Risk Osteosarcoma. JAMA Oncology, 2015, 1, 253.	3.4	30
87	Radionuclide Therapy for Osseous Metastases in Prostate Cancer. Seminars in Nuclear Medicine, 2015, 45, 66-80.	2.5	21
88	Treatment of castrationâ€resistant prostate cancer and bone metastases with radiumâ€223 dichloride. International Journal of Urological Nursing, 2015, 9, 3-13.	0.1	17
89	Isolation of generator-produced 223Ra in 0.9-% NaCl solutions containing EDTA for direct radiotherapeutic studies. Journal of Radioanalytical and Nuclear Chemistry, 2015, 304, 449-453.	0.7	10
90	The status of radioimmunotherapy in CD20+ non-Hodgkinâ€™s lymphoma. Targeted Oncology, 2015, 10, 15-26.	1.7	18
91	Radium-223 Therapy for Patients with Metastatic Castrate-Resistant Prostate Cancer: An Update on Literature with Case Presentation. International Journal of Molecular Imaging, 2016, 2016, 1-12.	1.3	18
92	Contemporary agents in the management of metastatic castration-resistant prostate cancer. Canadian Urological Association Journal, 2016, 10, 414.	0.3	24
93	Targeted Radionuclide Therapy of Human Tumors. International Journal of Molecular Sciences, 2016, 17, 33.	1.8	130
94	Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial. European Urology, 2016, 70, 875-883.	0.9	67
95	A Monte Carlo study on ²²³Ra imaging for unsealed radionuclide therapy. Medical Physics, 2016, 43, 2965-2974.	1.6	17

#	Article	IF	Citations
96	Development of a transmission alpha particle dosimetry technique using A549 cells and a Raâ€223 source for targeted alpha therapy. Medical Physics, 2016, 43, 6145-6153.	1.6	10
97	Radium-223 dichloride in clinical practice: a review. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1896-1909.	3.3	29
98	Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle. Expert Opinion on Biological Therapy, 2016, 16, 1035-1047.	1.4	119
99	Prostate-Specific Antigen Flare Phenomenon During 223Ra-Dichloride Treatment for Bone Metastatic Castration-Resistant Prostate Cancer: A Case Report. Clinical Genitourinary Cancer, 2016, 14, e529-e533.	0.9	21
100	Radium-223 Therapy of Bone Metastases in Prostate Cancer. Seminars in Nuclear Medicine, 2016, 46, 544-556.	2.5	10
101	Chemotherapy following radiumâ€223 dichloride treatment in ALSYMPCA. Prostate, 2016, 76, 905-916.	1.2	58
102	Subacute Stroke Mimicking Cerebral Metastasis in 68Ga-PSMA-HBED-CC PET/CT. Clinical Nuclear Medicine, 2016, 41, e449-e451.	0.7	53
103	Human absorbed dose estimation for a new 175Yb-phosphonate based on rats data: Comparison with similar bone pain palliation agents. Applied Radiation and Isotopes, 2016, 115, 55-60.	0.7	0
104	Clinical experience with radium-223 in the treatment of patients with advanced castrate-resistant prostate cancer and symptomatic bone metastases. Therapeutic Advances in Urology, 2016, 8, 175-180.	0.9	17
105	From palliative therapy to prolongation of survival: ²²³RaCl₂ in the treatment of bone metastases. Therapeutic Advances in Medical Oncology, 2016, 8, 294-304.	1.4	19
106	Radiotherapy cannot prolong overall survival of young prostate cancer patients with bone metastases. Journal of Translational Medicine, 2016, 14, 102.	1.8	2
107	Therapeutic Radiopharmaceuticals for Bone Pain Palliation. , 2016, , 225-252.		2
108	210Po poisoning as possible cause of death: forensic investigations and toxicological analysis of the remains of Yasser Arafat. Forensic Science International, 2016, 259, 1-9.	1.3	6
109	Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer. Cancer Treatment Reviews, 2016, 44, 61-73.	3.4	56
110	Treatment of Metastatic Bone Disease and the Emerging Role of Radium-223. Seminars in Nuclear Medicine, 2016, 46, 99-104.	2.5	47
111	Nuclear medicine and the revolution in the modern management of castration-resistant prostate cancer patients: from 223Ra-dichloride to new horizons for therapeutic response assessment. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 5-7.	3.3	6
112	Managing Metastatic Castration-Resistant Prostate Cancer in the Pre-chemotherapy Setting: A Changing Approach in the Era of New Targeted Agents. Drugs, 2016, 76, 421-430.	4.9	4
113	Radium-223 dichloride in castration-resistant prostate cancer with symptomatic bone metastases: a guide to its use. Drugs and Therapy Perspectives, 2016, 32, 98-103.	0.3	0

#	Article	IF	Citations
114	Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer. Current Oncology Reports, 2016, 18, 14.	1.8	39
115	Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting 223Ra-dichloride. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 21-33.	3.3	116
116	Targeted Radionuclide Therapy. , 2016, , 399-418.e14.		4
117	Treatment landscape of metastatic prostate cancer: the role of radium-223. Acta Clinica Belgica, 2017, 72, 19-23.	0.5	1
118	A Retrospective Analysis of the First 41 mCRPC Patients with Bone Pain Treated with Radium-223 at the National Institute of Oncology in Hungary. Pathology and Oncology Research, 2017, 23, 777-783.	0.9	5
119	Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases. International Journal of Clinical Oncology, 2017, 22, 954-963.	1.0	11
120	Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1671-1678.	3.3	47
121	Therapies for castrationâ€resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines. International Journal of Urology, 2017, 24, 566-572.	0.5	22
122	A radiobiological model of metastatic burden reduction for molecular radiotherapy: application to patients with bone metastases. Physics in Medicine and Biology, 2017, 62, 2859-2870.	1.6	6
123	Acute Myeloid Leukemia After Radium-223 Therapy: Case Report. Clinical Genitourinary Cancer, 2017, 15, e723-e726.	0.9	10
124	Clinical Correlates of Benefit From Radiumâ€223 Therapy in Metastatic Castration Resistant Prostate Cancer. Prostate, 2017, 77, 479-488.	1.2	39
125	Radiopharmaceuticals for metastatic bone pain palliation: available options in the clinical domain and their comparisons. Clinical and Experimental Metastasis, 2017, 34, 1-10.	1.7	23
126	Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases. Expert Review of Clinical Pharmacology, 2017, 10, 809-819.	1.3	3
127	Lymphocyte function following radium-223 therapy in patients with metastasized, castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 242-246.	3.3	10
128	A Radium-223 microgenerator from cyclotron-produced trace Actinium-227. Applied Radiation and Isotopes, 2017, 119, 36-42.	0.7	33
129	Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial. Clinical Genitourinary Cancer, 2017, 15, 42-52.e8.	0.9	75
130	Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy. Cancers, 2017, 9, 13.	1.7	40
131	Radium 223 dichloride for prostate cancer treatment. Drug Design, Development and Therapy, 2017, Volume 11, 2643-2651.	2.0	65

#	Article	IF	Citations
132	Ra-223 SPECT for semi-quantitative analysis in comparison with Tc-99m HMDP SPECT: phantom study and initial clinical experience. EJNMMI Research, 2017, 7, 81.	1.1	19
133	Usefulness of Radium-223 in Patients with Bone Metastases. Baylor University Medical Center Proceedings, 2017, 30, 424-426.	0.2	11
134	Treatment of Bone Metastasis with Bone-Targeting Radiopharmaceuticals. Nuclear Medicine and Molecular Imaging, 2018, 52, 200-207.	0.6	31
135	Current perspectives on bone metastases in castrate-resistant prostate cancer. Cancer and Metastasis Reviews, 2018, 37, 189-196.	2.7	66
136	Lymph Node Response in a Patient With Metastatic Castration-resistant Prostate Cancer Treated With Radium-223. Clinical Genitourinary Cancer, 2018, 16, e397-e401.	0.9	8
137	Progression to bone-marrow carcinomatosis and extraosseous legion during treatment with radium-223 for multiple bone metastases. International Cancer Conference Journal, 2018, 7, 48-51.	0.2	3
138	Optimizing the treatment of metastatic castration-resistant prostate cancer: a Latin America perspective. Medical Oncology, 2018, 35, 56.	1.2	4
139	Radio-223 en la secuencia terapÃ©utica del cÃ¡ncer de prÃ³stata resistente a la castraciÃ³n metastÃ¡sico. Actas UrolÃ³gicas EspaÃ±olas, 2018, 42, 227-237.	0.3	2
140	Optical emission of ²²³Radium: in vitro and in vivo preclinical applications. Journal of Biophotonics, 2018, 11, e201700209.	1.1	3
141	The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2018, 16, e223-e231.	0.9	27
142	223Ra-dichloride therapy in an elderly bone metastatic castration-resistant prostate cancer patient: a case report presentation and comparison with existing literature. Aging Clinical and Experimental Research, 2018, 30, 677-680.	1.4	21
143	Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis. Calcified Tissue International, 2018, 102, 152-162.	1.5	29
144	Combining anticancer drugs with osteoprotective agents in prostate cancerâ€"A contemporary update. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 488-497.	0.8	0
145	Targeted Alpha Therapy, an Emerging Class of Cancer Agents. JAMA Oncology, 2018, 4, 1765.	3.4	143
147	Fluorine-18-fluorocholine PET/CT parameters predictive for hematological toxicity to radium-223 therapy in castrate-resistant prostate cancer patients with bone metastases. Nuclear Medicine Communications, 2018, 39, 672-679.	0.5	13
148	Targeted alpha therapy using Radium-223: From physics to biological effects. Cancer Treatment Reviews, 2018, 68, 47-54.	3.4	28
149	²²³Ra-chloride therapy in men with hormone-refractory prostate cancer and skeletal metastases: Real-world experience. Tumori, 2018, 104, 128-136.	0.6	14
150	The impact of age on radium-223 distribution and an evaluation of molecular imaging surrogates. Nuclear Medicine and Biology, 2018, 62-63, 1-8.	0.3	14

#	Article	IF	Citations
151	Alkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarker. Future Oncology, 2018, 14, 2543-2556.	1.1	48
152	Dosimetry. , 2018, , 393-403.		0
153	Novel Approaches of Treatment with Radium-223 Targeted Therapy. , 2018, , 379-391.		0
154	Pharmacological Risk Assessment for Dental Implants. , 2018, , 37-65.		0
155	Targeted Î± Therapies for the Treatment of Bone Metastases. International Journal of Molecular Sciences, 2018, 19, 74.	1.8	23
156	Osteonecrosis of the Jaw in a Patient With Bone Metastatic Prostate Cancer After Long-term Bisphosphonate Treatment With Severe Deterioration Following Radium-223. Clinical Genitourinary Cancer, 2018, 16, 328-331.	0.9	4
157	Radium-223 in the therapeutic sequence of metastatic castration-resistant prostate cancer. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2018, 42, 227-237.	0.2	1
158	Advances in targeted alpha therapy for prostate cancer. Annals of Oncology, 2019, 30, 1728-1739.	0.6	43
159	Pain response in a population-based study of radium-223 (Ra223) for metastatic castration-resistant prostate cancer. Canadian Urological Association Journal, 2019, 13, E311-6.	0.3	5
160	Radium-223 mechanism of action: implications for use in treatment combinations. Nature Reviews Urology, 2019, 16, 745-756.	1.9	71
161	Engineered bone for probing organotypic growth and therapy response of prostate cancer tumoroids in vitro. Biomaterials, 2019, 197, 296-304.	5.7	18
162	Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program. BMC Cancer, 2019, 19, 12.	1.1	36
163	Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program. Clinical Genitourinary Cancer, 2019, 17, 348-355.e5.	0.9	27
164	No evidence of association between psychological distress and pain relief in patients with bone metastases from castrationâ€resistant prostate cancer treated with 223Radium. European Journal of Cancer Care, 2019, 28, e13112.	0.7	7
165	The evolution and understanding of skeletal complication endpoints in clinical trials of tumors with metastasis to the bone. Critical Reviews in Oncology/Hematology, 2019, 139, 108-116.	2.0	17
166	Initial Experience With Radium-223 Chloride Treatment at the Kanazawa University Hospital. Anticancer Research, 2019, 39, 2607-2614.	0.5	9
167	Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why. Tumori, 2019, 105, 367-377.	0.6	17
168	Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. European Journal of Cancer, 2019, 114, 107-116.	1.3	42

#	Article	IF	Citations
169	Personalized Radiation Therapy in Cancer Pain Management. Cancers, 2019, 11, 390.	1.7	17
170	Use of Radium-223 Dichloride in Patients With Osteonecrosis of the Jaw Induced by Zoledronic Acid: Report of 2 Cases. Clinical Genitourinary Cancer, 2019, 17, e612-e617.	0.9	3
171	Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases. International Journal of Clinical Oncology, 2019, 24, 557-566.	1.0	10
172	Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond. Endocrine-Related Cancer, 2019, 26, R31-R52.	1.6	49
173	Hematologic toxicity of radium-223 in elderly patients with metastatic Castration Resistant Prostate Cancer: aAreal-life experience. Prostate International, 2019, 7, 25-29.	1.2	10
174	Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial. Clinical Cancer Research, 2019, 25, 3802-3810.	3.2	42
175	Development of Targeted Alpha Particle Therapy for Solid Tumors. Molecules, 2019, 24, 4314.	1.7	82
176	Population-Based Analysis Of The Use Of Radium-223 For Bone-Metastatic Castration-Resistant Prostate Cancer In Ontario, And Of Factors Associated With Treatment Completion And Outcome . Cancer Management and Research, 2019, Volume 11, 9307-9319.	0.9	12
177	Radium 223-Mediated Zonal Cytotoxicity of Prostate Cancer in Bone. Journal of the National Cancer Institute, 2019, 111, 1042-1050.	3.0	20
178	Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in) Tj ETQq1 1 0.784314 rgBT /Ov prior use of chemotherapy in routine clinical practice. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1102-1110.	3.3	35
179	Radium-223 in combination with paclitaxel in cancer patients with bone metastases: safety results from an open-label, multicenter phase Ib study. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1092-1101.	3.3	13
180	Metastatic prostate cancer remains incurable, why?. Asian Journal of Urology, 2019, 6, 26-41.	0.5	103
181	Evidence of Local Concentration of Î±-Particles from ²¹¹At-Labeled Antibodies in Liver Metastasis Tissue. Journal of Nuclear Medicine, 2019, 60, 497-501.	2.8	14
184	Management of bone complications in patients with genitourinary malignancies. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 94-104.	0.8	1
185	Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes. JAMA Oncology, 2020, 6, 206.	3.4	22
186	Radiumâ€223 in Asian patients with castrationâ€resistant prostate cancer with symptomatic bone metastases: A singleâ€arm phase 3 study. Asia-Pacific Journal of Clinical Oncology, 2020, 17, 462-470.	0.7	6
187	Dynamic changes of bone metastasis predict boneâ€predominant status to benefit from radiumâ€223 dichloride for patients with castrationâ€resistant prostate cancer. Cancer Medicine, 2020, 9, 8579-8588.	1.3	14
188	Separation of actinium-227 and its daughter radium-223 from phosphogypsum. Journal of Radioanalytical and Nuclear Chemistry, 2020, 325, 463-470.	0.7	0

#	Article	IF	Citations
189	Bone metastases: a comprehensive review of the literature. Molecular Biology Reports, 2020, 47, 6337-6345.	1.0	28
190	Targeted Palliative Radionuclide Therapy for Metastatic Bone Pain. Journal of Clinical Medicine, 2020, 9, 2622.	1.0	22
191	Optimising Radium 223 Therapy for Metastatic Castration-Resistant Prostate Cancer â€“5-year Real-World Outcome: Focusing on Treatment Sequence and Quality of Life. Clinical Oncology, 2020, 32, e177-e187.	0.6	11
192	Histopathology of castration-resistant prostate cancer confirms changes in bone metastasis during radium-223 treatment: A case report. Urology Case Reports, 2020, 32, 101230.	0.1	1
193	Radium-223 as an Approved Modality for Treatment of Bone Metastases. Seminars in Nuclear Medicine, 2020, 50, 177-192.	2.5	28
194	Safety and activity of radium-223 in metastatic castration-resistant prostate cancer: the experience of Istituto Nazionale dei Tumori. Tumori, 2020, 106, 406-412.	0.6	5
195	An agent-based model of prostate Cancer bone metastasis progression and response to Radium223. BMC Cancer, 2020, 20, 605.	1.1	9
196	In situ Generated ²¹²Pb-PSMA Ligand in a ²²⁴Ra-Solution for Dual Targeting of Prostate Cancer Sclerotic Stroma and PSMA-positive Cells. Current Radiopharmaceuticals, 2020, 13, 130-141.	0.3	16
197	CApecitabine plus Radium-223 (Xofigoâ„¢) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial. Trials, 2020, 21, 89.	0.7	13
198	Morphometric vertebral fractures in patients with castration-resistant prostate cancer undergoing treatment with radium-223: a longitudinal study in the real-life clinical practice. Endocrine, 2020, 69, 204-211.	1.1	5
199	223-Radium for metastatic osteosarcoma: combination therapy with other agents and external beam radiotherapy. ESMO Open, 2020, 5, e000635.	2.0	13
200	Bone Metastases: Mechanisms of the Metastatic Process, Imaging and Therapy. Seminars in Ultrasound, CT and MRI, 2021, 42, 164-183.	0.7	0
201	¹⁷⁷Lu-EDTMP for Metastatic Bone Pain Palliation: A Systematic Review and Meta-Analysis. Cancer Biotherapy and Radiopharmaceuticals, 2021, 36, 383-390.	0.7	5
202	The Role of Theranostics in Prostate Cancer. Seminars in Radiation Oncology, 2021, 31, 71-82.	1.0	20
203	Radium-223 in combination with enzalutamide in metastatic castration-resistant prostate cancer: a multi-centre, phase II open-label study. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110426.	1.4	8
204	Combinatorial effect of radium-223 and irreversible electroporation on prostate cancer bone metastasis in mice. International Journal of Hyperthermia, 2021, 38, 650-662.	1.1	2
205	Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer. Cancers, 2021, 13, 779.	1.7	45
206	Exploiting bone niches: progression of disseminated tumor cells to metastasis. Journal of Clinical Investigation, 2021, 131, .	3.9	17

#	Article	IF	Citations
207	Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment. Clinical Cancer Research, 2021, 27, 3253-3264.	3.2	26
208	A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide. ESMO Open, 2021, 6, 100082.	2.0	2
209	Standardization of 223Ra by live-time anticoincidence counting and gamma-ray emission determination. Applied Radiation and Isotopes, 2021, 170, 109559.	0.7	4
210	Additive Benefits of Radium-223 Dichloride and Bortezomib Combination in a Systemic Multiple Myeloma Mouse Model. International Journal of Molecular Sciences, 2021, 22, 5570.	1.8	4
211	AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption. International Journal of Molecular Sciences, 2021, 22, 5515.	1.8	20
212	Radium-223 in the Third-Line Setting in Metastatic Castration-Resistant Prostate Cancer: Impact of Concomitant Use of Enzalutamide on Overall Survival (OS) and Predictors of Improved OS. Clinical Genitourinary Cancer, 2021, 19, 223-229.	0.9	6
213	Management of early-stage metastatic prostate cancer: appraisal of locoregional treatments and radiation therapy, with or without immunomodulation. Endocrine-Related Cancer, 2021, 28, T109-T120.	1.6	2
214	Celebrating the 80th anniversary of hormone ablation for prostate cancer. Endocrine-Related Cancer, 2021, 28, T1-T10.	1.6	4
215	Associations between osteoporosis and drug exposure: A post-marketing study of the World Health Organization pharmacovigilance database (VigiBaseÂ®). Bone, 2021, 153, 116137.	1.4	9
216	Targeted radionuclide therapy in bone cancer. , 2022, , 977-986.		0
217	Bone metastasesâ€"current status of bone-targeted treatments. , 2022, , 957-966.		0
218	Chapter 86. Radiotherapy of Skeletal Metastases. , 0, , 404-407.		1
219	Dose Painting and Theragnostic Imaging: Towards the Prescription, Planning and Delivery of Biologically Targeted Dose Distributions in External Beam Radiation Oncology. Cancer Treatment and Research, 2008, , 40-61.	0.2	11
220	Targeted High-LET Therapy of Bone Metastases. , 2008, , 181-194.		3
221	High-LET-Emitting Radionuclides for Cancer Therapy. , 2008, , 175-180.		1
222	Non-Surgical Treatment of Pulmonary and Extra-pulmonary Metastases. Cancer Treatment and Research, 2009, 152, 203-215.	0.2	2
223	Radiopharmaceuticals for Treatment of Osteosarcoma. Advances in Experimental Medicine and Biology, 2020, 1257, 45-53.	0.8	10
224	Bone Metastases. , 2008, , 845-871.		2

#	Article	IF	Citations
225	Bone Metastases. , 2014, , 739-763.e3.		3
227	Gold Coated Lanthanide Phosphate Nanoparticles for Targeted Alpha Generator Radiotherapy. PLoS ONE, 2013, 8, e54531.	1.1	99
228	Sublethal exposure to alpha radiation (223Ra dichloride) enhances various carcinomasâ€™ sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation. Oncotarget, 2016, 7, 86937-86947.	0.8	63
229	Radium-223 for primary bone metastases in patients with hormone-sensitive prostate cancer after radical prostatectomy. Oncotarget, 2017, 8, 44131-44140.	0.8	16
230	Targeted Radionuclide Therapy of Painful Bone Metastases: Past Developments, Current Status, Recent Advances and Future Directions. Current Medicinal Chemistry, 2020, 27, 3187-3249.	1.2	12
231	Applications of 211At and 223Ra in Targeted Alpha-Particle Radiotherapy. Current Radiopharmaceuticals, 2011, 4, 283-294.	0.3	62
232	Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer. Anticancer Research, 2016, 36, 5719-5730.	0.5	10
233	Scintigraphic load of bone disease evaluated by DASciS software as a survival predictor in metastatic castration-resistant prostate cancer patients candidates to 223RaCl treatment. Radiology and Oncology, 2019, 54, 40-47.	0.6	10
234	Application of ²¹²Pb for Targeted Î±-particle Therapy (TAT): Pre-clinical and Mechanistic Understanding through to Clinical Translation. AIMS Medical Science, 2015, 2, 228-245.	0.2	46
235	Radium-223 and metastatic castration-resistant prostate cancer: All that glitters is not gold. World Journal of Radiology, 2016, 8, 816.	0.5	4
236	Practical considerations for quantitative clinical SPECT/CT imaging of alpha particle emitting radioisotopes. Theranostics, 2021, 11, 9721-9737.	4.6	12
237	Prostate Cancer: Advanced and Metastatic Disease. UNIPA Springer Series, 2021, , 805-821.	0.1	0
238	Skeletal Complications: Bone Metabolism and Novel Targeted Agents. Translational Medicine Series, 2008, , 1-24.	0.0	0
239	4.6 Doses to Patients in Therapy. , 2012, , 231-240.		0
240	Intraperitoneal Radionuclide Therapy â€“ Clinical and Pre-Clinical Considerations. , 0, , .		1
244	Prostatakarzinom. , 2014, , 513-676.		0
245	Castration-Resistant Prostate Cancer (mCRPC): Shifting from Palliation to Improving Survival. Journal of Nuclear Medicine & Radiation Therapy, 2014, 06, .	0.2	0
246	Novel Radiopharmaceuticals for Therapy. , 2016, , 1-26.		0

#	Article	IF	Citations
247	Ra-223 dichloride management in a Nuclear Medicine Unit: experience of a referral institution. Journal of Radiology and Oncology, 2017, 1, 069-078.	0.2	1
248	Novel Radiopharmaceuticals for Therapy. , 2017, , 173-198.		0
249	InterdisziplinÃre Therapie von Knochenmetastasen. , 2018, , 71-94.		0
250	Radionuclide therapy with alpha-emitters. Radiation Diagnostics Radiation Therapy, 2019, , 37-47.	0.2	0
251	Radionuclide therapy with radium-223 chloride. A few strokes to the patientâ€™s portrait. Onkourologiya, 2019, 14, 87-94.	0.1	0
253	Enhancing ²²³Ra Treatment Efficacy by Anti-Î²1 Integrin Targeting. Journal of Nuclear Medicine, 2022, 63, 1039-1045.	2.8	6
254	Therapy Response Imaging in Genitourinary Malignancies. Medical Radiology, 2020, , 139-157.	0.0	0
255	Patient organ and effective dose estimation in radionuclide therapy with ²²³Ra -dichloride. RadiacionnaÃ¢ Gigiena, 2020, 13, 6-16.	0.2	0
256	Đ•fficiacy and safety of radium-223 in the treatment of metastatic castration-resistant prostate cancer. Meditsinskiy Sovet, 2020, , 70-82.	0.1	0
257	Single-center experience with radium-223 in patients with castration-resistant prostate cancer and bone metastases. Asian Journal of Andrology, 2020, 22, 437.	0.8	1
259	Dispersion of Alpha-Nuclides during Animal Experiments. Radiation Safety Management, 2021, 20, 29-38.	0.4	1
260	Chapter 33: Therapeutic Applications of Radioactive Agents. , 2020, , .		0
261	Prostatakarzinom. , 2014, , 513-676.		0
262	Radiopharmaceuticals for Prostate Cancer. , 2021, , 119-132.		0
263	Radium-223 therapy for metastatic castration-resistant prostate cancer: survival benefit when used earlier in the treatment pathway. Nuclear Medicine Communications, 2021, 42, 332-336.	0.5	15
265	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental Treatments in Pre-Clinical Studies (Cell Lines and Mouse Models). International Journal of Molecular Sciences, 2021, 22, 12297.	1.8	10
266	Safety and Efficacy of 177Lutetium-PSMA-617 Radioligand Therapy Shortly after Failing 223Radium-Dichloride. Cancers, 2022, 14, 557.	1.7	7
267	Comparison of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer After Docetaxel Failure: A Systematic Review and Network Meta-analysis. Frontiers in Pharmacology, 2021, 12, 789319.	1.6	9

#	Article	IF	Citations
268	Ra-223 and Ethinylestradiol Combination Therapy in Castration-resistant Prostate Cancer. Anticancer Research, 2022, 42, 1065-1071.	0.5	4
269	Side effects of therapy for bone metastasis with alpha and beta emitters. , 2022, , .		0
270	PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: Whatâ€™s Now, Whatâ€™s New, and Whatâ€™s Coming?. Cancers, 2022, 14, 907.	1.7	8
271	²²³Ra Induces Transient Functional Bone Marrow Toxicity. Journal of Nuclear Medicine, 2022, 63, 1544-1550.	2.8	2
274	Ocular complications with the use of radium-223: a case series. Radiation Oncology, 2022, 17, 97.	1.2	1
275	A phase IB and randomised phase IIA trial of CApecitabine plus Radium-223 (Xofigoâ„¢) in breast cancer patients with BONe metastases: CARBON trial results. Journal of Bone Oncology, 2022, 35, 100442.	1.0	5
276	Research and Development for Cyclotron Production of 225Ac from 226Raâ€”The Challenges in a Country Lacking Natural Resources for Medical Applications. Processes, 2022, 10, 1215.	1.3	10
277	Bone Metastases. , 2023, , 587-605.		0
278	Nuts and Bolts of²²³Ra-Dichloride Therapy. Journal of Nuclear Medicine Technology, 2022, 50, 215-221.	0.4	0
279	The global status of research in prostate cancer bone metastasis: A bibliometric and visualized analysis. Frontiers in Medicine, 0, 9, .	1.2	3
280	Radionuclide Therapy with Alpha-Emitting Agents in Bone Metastasis. , 2022, , 339-343.		0
281	Novel Radiopharmaceuticals for Therapy. , 2022, , 217-243.		0
282	Investigation into the Optimal Strategy of Radium-223 Therapy for Metastatic Castration-Resistant Prostate Cancer. Radiation, 2022, 2, 273-284.	0.6	3
283	Radiochemical Quality Control Methods for Radium-223 and Thorium-227 Radiotherapies. Cancer Biotherapy and Radiopharmaceuticals, 0, , .	0.7	2
284	Factors Influencing Outcome Postâ€“Radium-223 Dichloride in Castrate Resistant Prostate Cancer: A Review of Some Real-World Challenges. World Journal of Nuclear Medicine, 0, , .	0.3	0
285	Tumor growth inhibition and immune system activation following treatment with thorium-227 conjugates and PD-1 check-point inhibition in the MC-38 murine model. Frontiers in Medicine, 0, 9, .	1.2	1
286	Current and future targeted alpha particle therapies for osteosarcoma: Radium-223, actinium-225, and thorium-227. Frontiers in Medicine, 0, 9, .	1.2	2
287	Targeted alpha therapy with the 224Ra/212Pb-TCMC-TP-3 dual alpha solution in a multicellular tumor spheroid model of osteosarcoma. Frontiers in Medicine, 0, 9, .	1.2	4

#	Article	IF	Citations
288	Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatmentâ€"Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) Trial. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 1487-1498.	3.3	6
289	Dual targeting with 224Ra/212Pb-conjugates for targeted alpha therapy of disseminated cancers: A conceptual approach. Frontiers in Medicine, 0, 9, .	1.2	3
290	A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL). BMC Urology, 2023, 23, .	0.6	0
291	Navigating the mCRPC Landscape: Exploring Key Clinical Decision Points. European Medical Journal Urology, 0, , 57-62.	0.0	0
303	Case report: Exceptional and durable response to Radium-223 and suspension of androgen deprivation therapy in a metastatic castration-resistant prostate cancer patient. Frontiers in Oncology, 0, 14, .	1.3	0